Bioprocessing
-
Fujifilm Diosynth Biotechnologies Breaks Ground on Advanced Therapies Innovation Center
9-1-2020Fujifilm Diosynth Biotechnologies broke ground in August of 2020 on the $55 million Advanced Therapies Innovation Center in College Station, Texas.
-
Codiak BioSciences Installs G-CON PODs in Clinical Manufacturing Facility
8-19-2020Codiak BioSciences is constructing a 12,000-sf clinical manufacturing center in Lexington, Mass. The project includes the build-out of a leased lab and office building to create a GMP facility for the production of exosome therapeutics.
-
CRISPR Therapeutics Expands Research and Manufacturing Facilities
8-10-2020CRISPR Therapeutics signed a full-building lease in July of 2020 for a 263,500-sf facility in Boston's Seaport district.
-
Cell and Gene Therapy Catapult Plans COVID-19 Vaccine Production Center
8-5-2020The Cell and Gene Therapy Catapult is planning to create the Manufacturing Innovation Centre in Braintree in the United Kingdom. Supported by £100 million in government funding, the project will enable mass production of a COVID-19 vaccine.
-
MilliporeSigma Expands Research and Testing Facilities
7-23-2020MilliporeSigma, a subsidiary of Merck, is planning to expand its existing campus in Buchs, Switzerland, with the construction of a $20 million laboratory for the company's reference materials business. Accommodating 40 employees, the three-story, 12,000-sf struct
-
Wake Technical Community College Constructs Biotechnology Building
7-1-2020Wake Technical Community College is constructing the $33.4 million RTP2 building in Morrisville, N.C.
-
Ryvu Therapeutics Completes R&D Center for Innovative Drugs
6-9-2020Ryvu Therapeutics completed construction in June of 2020 on the R&D Center for Innovative Drugs in Krakow, Poland.
-
Catalent Increases Bloomington Manufacturing Capacity for SARS-CoV-2 Vaccine Candidate
6-4-2020Catalent is rapidly scaling up its manufacturing capacity in Bloomington to enable production of a SARS-CoV-2 vaccine candidate that is currently being by developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.
-
Exyte Partners with Univercells to Create Modular Vaccine Development Facilities
5-26-2020Exyte is partnering with Univercells Technologies to create modular biomanufacturing facilities to meet the increased global demand for vaccines during the SARS-CoV-2 pandemic.
-
Medicago Builds Vaccine Manufacturing Complex in Quebec City
5-20-2020Medicago is building a 646,000-sf vaccine manufacturing complex in Quebec City, Canada. Designed by NFOE, the facility will support the production of approximately 50 million doses of recombinant quadrivalent influenza vaccine per year.
